A 24-Year Mortality Analysis of Spinal Muscular Atrophy and a Blueprint for Future Pediatric Care
Episode Summary
A 24-year U.S. analysis shows gene-targeted therapies dramatically reduced childhood spinal muscular atrophy mortality, transforming a once-fatal disease into a manageable long-term condition.